SPRAVATO 28mg 3s (Esketamine Hydrochloride Nasal Spray) 28mg/0.2ml

Spravato 28mg nasal spray offers rapid-acting relief for treatment-resistant depression when used as directed. This esketamine-based nasal spray is designed for adult use under medical supervision. Store below 25°C and follow prescription guidelines. Discover how Spravato supports mental health management.

Strength

28mg/0.2ml

Pack Size

Storage

Below 25°C

Manufacturer / TM Owner

Janssen Pharmaceuticals Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Spravato 28mg nasal spray is primarily used to support treatment-resistant depression in adults. It is often prescribed when other antidepressant therapies have not provided sufficient relief. The medication works alongside oral antidepressants to enhance their effects. Patients may wonder, 'what is Spravato used for' as part of their mental health treatment plan.

Side Effects

Users may experience a calming or dissociative sensation shortly after administration, which typically subsides within the session. The nasal spray format allows for quick absorption and onset of action. Some individuals report improved mood stability following consistent use under professional guidance.

Precautions & Warnings

Spravato should be administered in a certified healthcare setting due to potential side effects like dizziness or sedation. Avoid operating machinery or driving for 24 hours post-dose. Keep the device sealed until use and store securely away from children. Always follow healthcare provider instructions for safe handling.

Avoid Interactions

Combining Spravato with alcohol or central nervous system depressants may increase sedation risk. Certain medications, including CYP3A4 inhibitors, can affect esketamine levels in the body. Discuss all current medications with your healthcare provider before starting Spravato. Monitor for heightened side effects when used alongside other antidepressants.

Frequently Asked Questions

Effects may be noticed during or shortly after administration, but consistent use over weeks is typically required for full benefits.

No, Spravato must be administered in a certified healthcare setting under professional supervision.

Dizziness, nausea, and dissociation are frequently reported during or after use.

Yes, Spravato is classified as a Schedule III controlled substance due to its potential for misuse.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.